Drug development and clinical trials—the path to an approved cancer drug
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug development and clinical trials—the path to an approved cancer drug
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 9, Issue 4, Pages 215-222
Publisher
Springer Nature
Online
2012-02-28
DOI
10.1038/nrclinonc.2012.22
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Implementing Personalized Medicine in a Cancer Center
- (2011) David A. Fenstermacher et al. CANCER JOURNAL
- Phase II Trials Powered to Detect Tumor Subtypes
- (2011) J. D. Roberts et al. CLINICAL CANCER RESEARCH
- Adaptive Clinical Trial Designs for Simultaneous Testing of Matched Diagnostics and Therapeutics
- (2011) H. I. Scher et al. CLINICAL CANCER RESEARCH
- MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts
- (2011) N. V. Rajeshkumar et al. CLINICAL CANCER RESEARCH
- The National Institute for Health and Clinical Excellence and Its Role in Assessing the Value of New Cancer Treatments in England and Wales
- (2011) R. Trowman et al. CLINICAL CANCER RESEARCH
- Phase I Trial of MK-0752 in Children With Refractory CNS Malignancies: A Pediatric Brain Tumor Consortium Study
- (2011) Maryam Fouladi et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall Survival As the Outcome for Randomized Clinical Trials With Effective Subsequent Therapies
- (2011) Edward L. Korn et al. JOURNAL OF CLINICAL ONCOLOGY
- Common Gene Rearrangements in Prostate Cancer
- (2011) Mark A. Rubin et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients WithBRCA1orBRCA2Mutations and Recurrent Ovarian Cancer
- (2011) Stan B. Kaye et al. JOURNAL OF CLINICAL ONCOLOGY
- Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites
- (2011) R. Montano et al. MOLECULAR CANCER THERAPEUTICS
- High drug attrition rates—where are we going wrong?
- (2011) Lisa Hutchinson et al. Nature Reviews Clinical Oncology
- Phase II failures: 2008–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Believe it or not: how much can we rely on published data on potential drug targets?
- (2011) Florian Prinz et al. NATURE REVIEWS DRUG DISCOVERY
- Early Accelerated Approval for Highly Targeted Cancer Drugs
- (2011) Bruce A. Chabner NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The BATTLE Trial: Personalizing Therapy for Lung Cancer
- (2011) Edward S. Kim et al. Cancer Discovery
- Final safety and efficacy analysis of the specific endothelin A receptor antagonist zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancer and bone metastases who were pain-free or mildly symptomatic for pain: a double-blind,
- (2010) Nicholas D. James et al. BJU INTERNATIONAL
- Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition
- (2010) A. Gualberto et al. CLINICAL CANCER RESEARCH
- Volumes to Learn: Advancing Therapeutics with Innovative Computed Tomography Image Data Analysis
- (2010) M. L. Maitland CLINICAL CANCER RESEARCH
- A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development
- (2010) B. Zhao et al. CLINICAL CANCER RESEARCH
- Multiplicity Adjustment Big and Small in Clinical Studies
- (2010) J C Hsu CLINICAL PHARMACOLOGY & THERAPEUTICS
- Trends in Risks Associated With New Drug Development: Success Rates for Investigational Drugs
- (2010) J A DiMasi et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Making the best of PARP inhibitors in ovarian cancer
- (2010) Susana Banerjee et al. Nature Reviews Clinical Oncology
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Use of Volumetric CT as an Imaging Biomarker in Lung Cancer
- (2009) Andrew J. Buckler et al. ACADEMIC RADIOLOGY
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Detecting an Overall Survival Benefit that Is Derived From Progression-Free Survival
- (2009) Kristine R. Broglio et al. JNCI-Journal of the National Cancer Institute
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- On the Eve of Personalized Medicine in Oncology
- (2008) T. J. Yeatman et al. CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search